VIDEO: Optogenetic therapy shows promise in advanced retinitis pigmentosa
Click Here to Manage Email Alerts
In this Healio Video Perspective, SriniVas R. Sadda, MD, discusses his paper on Nanoscope’s MCO-010 optogenetic therapy in advanced retinitis pigmentosa, which was presented at the Euretina congress in Amsterdam.
Sadda said he is “very excited” about the prospects of optogenetic therapy. Retinitis pigmentosa is the most common inherited retinal disease and is challenging because a number of mutations can cause the disease. This is why having a gene-agnostic type of treatment is going to be important, he said.
In the RESTORE phase 2b clinical trial, a substantial number of patients treated with MCO-010 demonstrated a response in vision-guided mobility, shape discrimination and visual acuity.
The safety profile of MCO-010 was good, with a few cases of inflammation, which were easily managed.
Collapse
Sadda SR. Optogenetic therapy with MCO-010 in severe sight loss due to retinitis pigmentosa: 12 month results from the RESTORE randomized, placebo-controlled double-masked clinical trial. Presented at: Euretina congress; Oct. 5-8, 2023; Amsterdam.
Read more about
Click Here to Manage Email Alerts